Shuttle Pharmaceuticals (NASDAQ:SHPH) Shares Down 1.8% – What’s Next?

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH)’s share price fell 1.8% on Wednesday. The stock traded as low as $4.76 and last traded at $4.82. 6,294 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 41,927 shares. The stock had previously closed at $4.91.

Analyst Upgrades and Downgrades

SHPH has been the subject of a number of analyst reports. Weiss Ratings raised Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, October 14th. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has an average rating of “Sell”.

Shuttle Pharmaceuticals Trading Up 5.4%

The firm’s fifty day moving average is $4.03 and its 200 day moving average is $4.93. The company has a market cap of $23.13 million, a PE ratio of -0.26 and a beta of 0.11.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company focused on developing therapies intended to improve outcomes for patients receiving radiation treatment for cancer. Its research centers on radiosensitizers, which are designed to make tumor cells more responsive to radiation while potentially limiting damage to surrounding healthy tissue.

The company’s lead product candidate is ropidoxuridine, an orally administered investigational radiosensitizer being studied for use in combination with radiation therapy.